Independent directory Public ClinicalTrials.gov records United States
Clinical Trials Finder
Objective public record navigation
Search Results

Search by objective public record fields.

Search by query text, NCT ID, condition, intervention, sponsor, city, state, recruitment status, phase, study type, healthy volunteer eligibility, sex, or age. Results come from ClinicalTrials.gov. When the live registry is unavailable, a clearly labeled stored copy may be shown.

Clear filters

These results were retrieved from the live ClinicalTrials.gov registry. Filters and sort order apply to this result list.

ClinicalTrials.gov public records Last synced Oct 13, 2026, 10:44 PM EDT

Data is sourced from official ClinicalTrials.gov public API records. Always review the official ClinicalTrials.gov record for the latest information.

Showing 121–144 of 773 matching trials from the live ClinicalTrials.gov search.
Filters: Condition: Cardiovascular Disease Prevention Clear all
Completed Phase 4 Interventional

Apixaban vs Rivaroxaban vs No Anticoagulant to Prevent EHIT After Great Saphenous Vein Laser Ablation

NCT07699796
View directory record Official record
Conditions
Venous Thrombosis Deep (Limbs), Venous Insufficiency (Chronic)(Peripheral), Varicose Veins Leg, Venous Thrombosis
Interventions
Apixaban, Rivaroxaban
Drug
Lead sponsor
Heart, Artery, and Vein Center of Fresno
Other
Eligibility
18 Years and older
Enrollment
564 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2018 – 2021
U.S. locations
1
States / cities
Fresno, California
Source: ClinicalTrials.gov public record
Updated Jul 16, 2026 · Synced Oct 13, 2026, 10:44 PM EDT
Terminated Phase 2 Interventional Results available

Ceftriaxone to PRevent pneumOnia and inflammatTion aftEr Cardiac arresT (PROTECT)

NCT04999592
View directory record Official record
Conditions
Out-Of-Hospital Cardiac Arrest, Pneumonia
Interventions
Standard of care without prophylaxis, Antibiotic prophylaxis
Drug
Lead sponsor
David J. Gagnon
Other
Eligibility
18 Years and older
Enrollment
53 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2021 – 2024
U.S. locations
1
States / cities
Portland, Maine
Source: ClinicalTrials.gov public record
Updated Apr 17, 2025 · Synced Oct 13, 2026, 10:44 PM EDT
Enrolling by invitation No phase listed Observational Accepts healthy volunteers

The Diabetes Prevention Program Outcomes Study AD/ADRD Project

NCT05704309
View directory record Official record
Conditions
Diabetes, Alzheimer Disease, Dementia, Vascular, Dementia, PreDiabetes
Interventions
Not listed
Lead sponsor
Marinella Temprosa
Other
Eligibility
Not listed
Enrollment
1,976 participants
Healthy volunteers
Accepts healthy volunteers
Timeline
2022 – 2027
U.S. locations
27
States / cities
Phoenix, Arizona • Alhambra, California • San Diego, California + 21 more
Source: ClinicalTrials.gov public record
Updated Aug 26, 2025 · Synced Oct 13, 2026, 10:44 PM EDT
Completed Phase 3 Interventional Results available

Study of an Investigational Drug for the Prevention of Thrombosis-related Events Following Hip Replacement Surgery (ADVANCE-3)

NCT00423319
View directory record Official record
Conditions
Deep Vein Thrombosis, Pulmonary Embolism
Interventions
Enoxaparin, Apixaban, Enoxaparin-matching placebo, Apixaban-matching placebo
Drug
Lead sponsor
Bristol-Myers Squibb
Industry
Eligibility
18 Years and older
Enrollment
5,407 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2007 – 2009
U.S. locations
19
States / cities
Birmingham, Alabama • Little Rock, Arkansas • Sacramento, California + 12 more
Source: ClinicalTrials.gov public record
Updated May 14, 2014 · Synced Oct 13, 2026, 10:44 PM EDT
Not listed Phase 4 Interventional

Weight Based Enoxaparin in Trauma Patients

NCT01916707
View directory record Official record
Conditions
Venous Thromboembolism
Interventions
Dosing of enoxaparin for VTE prophylaxis
Drug
Lead sponsor
Intermountain Health Care, Inc.
Other
Eligibility
18 Years and older
Enrollment
1,200 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2013 – 2017
U.S. locations
1
States / cities
Murray, Utah
Source: ClinicalTrials.gov public record
Updated Apr 5, 2017 · Synced Oct 13, 2026, 10:44 PM EDT
Terminated No phase listed Observational

Comparison of the Risk of Venous Thromboembolism (i.e., Blood Clots in the Veins) and Bleeding Events in a Population of Obese Patients Receiving Higher-Dose or Extended-Duration Versus Conventional-Dose or Conventional-Duration of Prophylaxis (i.e., Preventive Treatment) With Enoxaparin

NCT05819125
View directory record Official record
Conditions
Venous Thromboembolism
Interventions
Not listed
Lead sponsor
Sanofi
Industry
Eligibility
40 Years and older
Enrollment
21,000 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2023
U.S. locations
1
States / cities
Bridgewater, New Jersey
Source: ClinicalTrials.gov public record
Updated Oct 29, 2024 · Synced Oct 13, 2026, 10:44 PM EDT
Completed Not applicable Interventional Results available

Deep Vein Thrombosis (DVT) Prevention in Total Hip Arthroplasty: Continuous Enhanced Circulation Therapy (CECT) Versus Low Molecular Weight Heparin (LMWH)

NCT00358735
View directory record Official record
Conditions
Deep Vein Thrombosis of Lower Limb, Pulmonary Embolism (PE), Bleeding
Interventions
ActiveCare CECT device, Enoxaparin
Device · Drug
Lead sponsor
Medical Compression Systems
Industry
Eligibility
18 Years and older
Enrollment
411 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2006 – 2008
U.S. locations
9
States / cities
La Jolla, California • Loma Linda, California • Los Angeles, California + 6 more
Source: ClinicalTrials.gov public record
Updated Oct 30, 2014 · Synced Oct 13, 2026, 10:44 PM EDT
Completed Phase 3 Interventional Results available

Apixaban in Preventing Secondary Cancer Related Venous Thrombosis in Cancer Patients Who Have Completed Anticoagulation Therapy

NCT03080883
View directory record Official record
Conditions
Cerebral Vein Thrombosis, Deep Vein Thrombosis, Hematopoietic and Lymphoid Cell Neoplasm, Malignant Solid Neoplasm, Metastatic Malignant Solid Neoplasm, Pulmonary Embolism, Splanchnic Vein Thrombosis
Interventions
Apixaban
Drug
Lead sponsor
Academic and Community Cancer Research United
Other
Eligibility
18 Years and older
Enrollment
370 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2017 – 2025
U.S. locations
32
States / cities
Scottsdale, Arizona • Washington D.C., District of Columbia • Jacksonville, Florida + 27 more
Source: ClinicalTrials.gov public record
Updated May 18, 2025 · Synced Oct 13, 2026, 10:44 PM EDT
Completed Phase 4 Interventional Results available

Seizure Prophylaxis in Aneurysm Repair

NCT01801072
View directory record Official record
Conditions
Intracranial Aneurysms, Seizure
Interventions
Levetiracetam
Drug
Lead sponsor
University of Michigan
Other
Eligibility
18 Years and older
Enrollment
82 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2013 – 2023
U.S. locations
1
States / cities
Ann Arbor, Michigan
Source: ClinicalTrials.gov public record
Updated Nov 29, 2024 · Synced Oct 13, 2026, 10:44 PM EDT
Completed Not applicable Interventional Accepts healthy volunteers Results available

The Clinical Referral to Activity Study

NCT04743856
View directory record Official record
Conditions
Physical Inactivity, Cardiovascular Risk Factor, Obesity, Blood Pressure, PreDiabetes
Interventions
ActiveGOALSv2, PAT
Behavioral
Lead sponsor
University of Pittsburgh
Other
Eligibility
40 Years to 70 Years
Enrollment
54 participants
Healthy volunteers
Accepts healthy volunteers
Timeline
2022 – 2024
U.S. locations
1
States / cities
Pittsburgh, Pennsylvania
Source: ClinicalTrials.gov public record
Updated May 12, 2026 · Synced Oct 13, 2026, 10:44 PM EDT
Withdrawn Not applicable Interventional

Can the Lambre Device Occlude IRRegular And Large Appendages in Patients With Non-Valvular AF

NCT04684212
View directory record Official record
Conditions
Atrial Fibrillation, Left Atrial Appendage Thrombosis, CVA
Interventions
LAmbre PlusTM Left Atrial Appendage Closure System, Market approved oral anticoagulation (OAC), such as warfarin (Coumadin), dabigatran (Pradaxa), rivaroxaban (Xarelto), apixiban (Eliquis), edoxaban (Savaysa), or betrixaban (Bevyxxa)
Device · Drug
Lead sponsor
Brian O'Neill MD
Other
Eligibility
18 Years and older
Healthy volunteers
Healthy volunteers not accepted
Timeline
2024
U.S. locations
1
States / cities
Detroit, Michigan
Source: ClinicalTrials.gov public record
Updated Nov 4, 2025 · Synced Oct 13, 2026, 10:44 PM EDT
Completed Phase 3 Interventional Results available

Reduced-dosed Rivaroxaban in the Long-term Prevention of Recurrent Symptomatic VTE(Venous Thromboembolism)

NCT02064439
View directory record Official record
Conditions
Pulmonary Embolism, Thromboembolism, Thrombosis, Venous Thrombosis, Venous Thromboembolism
Interventions
BAY 59-7939, ASA
Drug
Lead sponsor
Bayer
Industry
Eligibility
18 Years and older
Enrollment
3,365 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2014 – 2016
U.S. locations
24
States / cities
Beverly Hills, California • La Jolla, California • Ventura, California + 19 more
Source: ClinicalTrials.gov public record
Updated Dec 19, 2017 · Synced Oct 13, 2026, 10:44 PM EDT
Completed Phase 2 Interventional Results available

The SCCS Polypill Pilot Trial

NCT02278471
View directory record Official record
Conditions
Hypertension, Hyperlipidemia
Interventions
Polypill (atorvastatin, amlodipine, losartan, and hydrochlorothiazide)
Drug
Lead sponsor
Vanderbilt University
Other
Eligibility
45 Years to 75 Years
Enrollment
303 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2015 – 2018
U.S. locations
1
States / cities
Mobile, Alabama
Source: ClinicalTrials.gov public record
Updated May 14, 2021 · Synced Oct 13, 2026, 10:44 PM EDT
Completed No phase listed Observational Accepts healthy volunteers

Improving Prevention of Heart Disease in Latinos

NCT00101530
View directory record Official record
Conditions
Cardiovascular Diseases, Heart Diseases, Hypertension, Diabetes Mellitus
Interventions
Not listed
Lead sponsor
University of Colorado, Denver
Other
Eligibility
21 Years and older
Enrollment
179 participants
Healthy volunteers
Accepts healthy volunteers
Timeline
2004 – 2012
U.S. locations
1
States / cities
Denver, Colorado
Source: ClinicalTrials.gov public record
Updated Oct 1, 2015 · Synced Oct 13, 2026, 10:44 PM EDT
Withdrawn Not applicable Interventional

Efficacy of Vasculera in Prevention on Post-op Pain and Edema Following Lower Extremity Venous Treatment in the Outpatient Setting

NCT02936271
View directory record Official record
Conditions
Venous Insufficiency of Leg, Venous Reflux, Varicose Veins, Lower Extremity Edema Chronic
Interventions
Vasculera, Placebo
Other
Lead sponsor
Corewell Health West
Other
Eligibility
18 Years to 85 Years
Healthy volunteers
Healthy volunteers not accepted
Timeline
2016 – 2017
U.S. locations
1
States / cities
Grand Rapids, Michigan
Source: ClinicalTrials.gov public record
Updated Nov 23, 2022 · Synced Oct 13, 2026, 10:44 PM EDT
Recruiting Phase 3 Interventional

REGN7508 Versus Acetylsalicylic Acid (ASA) for Venous Thromboprophylaxis After Total Knee Arthroplasty in Adult Participants

NCT07213778
View directory record Official record
Conditions
Symptomatic Venous Thromboembolism (VTE)
Interventions
REGN7508, Acetylsalicylic Acid (ASA), Placebo
Drug
Lead sponsor
Regeneron Pharmaceuticals
Industry
Eligibility
18 Years and older
Enrollment
2,000 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2025 – 2027
U.S. locations
36
States / cities
La Mesa, California • Rancho Mirage, California • Riverside, California + 28 more
Source: ClinicalTrials.gov public record
Updated Oct 8, 2026 · Synced Oct 13, 2026, 10:44 PM EDT
Completed Phase 3 Interventional Results available

Acute Medically Ill VTE Prevention With Extended Duration Betrixaban Study (The APEX Study)

NCT01583218
View directory record Official record
Conditions
Venous Thromboembolism (VTE)
Interventions
Betrixaban, Enoxaparin
Drug
Lead sponsor
Portola Pharmaceuticals
Industry
Eligibility
40 Years and older
Enrollment
7,513 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2012 – 2016
U.S. locations
75
States / cities
Birmingham, Alabama • Bakersfield, California • Fresno, California + 69 more
Source: ClinicalTrials.gov public record
Updated Aug 7, 2023 · Synced Oct 13, 2026, 10:44 PM EDT
Withdrawn Phase 4 Interventional

Aggressive Risk-Prevention Therapies for Coronary Atherosclerotic Plaque (ART-CAP)

NCT06280976
View directory record Official record
Conditions
Coronary Artery Disease, Atherosclerosis, Heart Attack
Interventions
Statin, Aspirin tablet, Nexlizet, LEQVIO, Vascepa, Jardiance, Colchicine
Drug
Lead sponsor
University of Louisville
Other
Eligibility
18 Years to 80 Years
Healthy volunteers
Healthy volunteers not accepted
Timeline
2024 – 2025
U.S. locations
1
States / cities
Louisville, Kentucky
Source: ClinicalTrials.gov public record
Updated Mar 17, 2025 · Synced Oct 13, 2026, 10:44 PM EDT
Completed Not applicable Interventional

Cholesterol, Hypertension and Glucose Education Study

NCT00815789
View directory record Official record
Conditions
Cardiovascular Disease, Diabetes
Interventions
Tailored cardiovascular risk management (Nurse-administered )
Behavioral
Lead sponsor
Duke University
Other
Eligibility
18 Years and older
Enrollment
362 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2008 – 2011
U.S. locations
1
States / cities
Durham, North Carolina
Source: ClinicalTrials.gov public record
Updated Nov 15, 2023 · Synced Oct 13, 2026, 10:44 PM EDT
Terminated Phase 1Phase 2 Interventional Results available

Th1/Tc1 Immunotherapy Following Stem Cell Transplantation in Multiple Myeloma

NCT01239368
View directory record Official record
Conditions
Myeloma, Plasma-Cell, Myeloma-Multiple, Myelomatosis
Interventions
Adoptive Immunotherapy, Rapamycin-Generated Autologous Th1/Tc1 Cells (modified primary human T cells), Th1/Tc1 Rapa Cell Therapy
Procedure · Biological
Lead sponsor
National Cancer Institute (NCI)
NIH
Eligibility
18 Years to 75 Years
Enrollment
34 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2010 – 2017
U.S. locations
2
States / cities
Bethesda, Maryland • Hackensack, New Jersey
Source: ClinicalTrials.gov public record
Updated Dec 10, 2019 · Synced Oct 13, 2026, 10:44 PM EDT
Completed Not applicable Interventional Accepts healthy volunteers Results available

The LEARN Study for CVD Prevention

NCT05242952
View directory record Official record
Conditions
Cardiovascular Diseases
Interventions
Gaming in a virtual environment
Behavioral
Lead sponsor
Yale University
Other
Eligibility
30 Years to 65 Years · Male only
Enrollment
78 participants
Healthy volunteers
Accepts healthy volunteers
Timeline
2023 – 2025
U.S. locations
1
States / cities
Orange, Connecticut
Source: ClinicalTrials.gov public record
Updated Jul 16, 2026 · Synced Oct 13, 2026, 10:44 PM EDT
Completed Phase 3 Interventional

Secondary Prevention of Small Subcortical Strokes Trial

NCT00059306
View directory record Official record
Conditions
Cerebrovascular Accident, Hypertension
Interventions
aspirin, clopidogrel, Target of Blood Pressure, placebo
Drug · Other
Lead sponsor
University of British Columbia
Other
Eligibility
30 Years and older
Enrollment
3,020 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2003 – 2012
U.S. locations
39
States / cities
Mobile, Alabama • Phoenix, Arizona • Scottsdale, Arizona + 32 more
Source: ClinicalTrials.gov public record
Updated Apr 4, 2013 · Synced Oct 13, 2026, 10:44 PM EDT
Not listed No phase listed Observational Accepts healthy volunteers

Doppler Ultrasound Imaging of Plastic Surgery Patients for DVT Detection

NCT02123550
View directory record Official record
Conditions
Deep Venous Thrombosis
Interventions
Not listed
Lead sponsor
Swanson Center
Other
Eligibility
18 Years and older
Enrollment
2,000 participants
Healthy volunteers
Accepts healthy volunteers
Timeline
2014 – 2022
U.S. locations
1
States / cities
Leawood, Kansas
Source: ClinicalTrials.gov public record
Updated Sep 10, 2018 · Synced Oct 13, 2026, 10:44 PM EDT
Completed Phase 3 Interventional Results available

Evaluation of Efficacy and Safety of Lovaza (Omega-3-Acid Ethyl Esters) in Recurrent, Symptomatic Atrial Fibrillation

NCT00402363
View directory record Official record
Conditions
Fibrillation, Atrial
Interventions
omega-3-acid ethyl esters, Placebo
Drug
Lead sponsor
GlaxoSmithKline
Industry
Eligibility
18 Years and older
Enrollment
663 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2006 – 2010
U.S. locations
178
States / cities
Birmingham, Alabama • Huntsville, Alabama • Anchorage, Alaska + 149 more
Source: ClinicalTrials.gov public record
Updated Jan 30, 2017 · Synced Oct 13, 2026, 10:44 PM EDT